Wheless, James W. http://orcid.org/0000-0002-4735-3431
Gidal, Barry http://orcid.org/0000-0001-6681-7134
Rabinowicz, Adrian L. http://orcid.org/0000-0003-1299-0606
Carrazana, Enrique http://orcid.org/0000-0001-8788-0722
Funding for this research was provided by:
Neurelis, Inc.
Article History
Accepted: 29 September 2023
First Online: 30 October 2023
Declarations
:
: Development of this article was funded by Neurelis, Inc.
: James W. Wheless has served as an advisor or consultant for CombiMatrix, Eisai Inc., GW Pharmaceuticals, Lundbeck, Inc., Neurelis, Inc., NeuroPace, Inc., Supernus Pharmaceuticals, Inc., and Upsher-Smith Laboratories, Inc. Dr Wheless has served as a speaker or a member of a speakers bureau for Cyberonics, Inc., Eisai Inc., Lundbeck, Inc., Mallinckrodt, Neurelis, Inc., Supernus Pharmaceuticals, Inc., and Upsher-Smith Laboratories, Inc., and has received grants for clinical research from Acorda Therapeutics, GW Pharmaceuticals, Insys Therapeutics, Inc., Lundbeck, Inc., Mallinckrodt, Neurelis, Inc., NeuroPace, Inc., Upsher-Smith Laboratories, Inc., and Zogenix, Inc. Barry Gidal is a consultant for Aquestive, Eisai Inc., Greenwich, Neurelis, Inc., and SK Life Science, is a member of the End Point Review Committee for Sunovion Pharmaceuticals Inc, and has a grant/contract with UCB Inc. Enrique Carrazana is an employee of and has received stock and stock options from Neurelis, Inc. Adrian L. Rabinowicz is an employee of and has received stock options from Neurelis, Inc.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors made a significant contribution to the work reported, whether that is in the conception, execution, acquisition of data, or analysis and interpretation, or in all these areas; took part in drafting, revising, or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.